- Conditions
- Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Recurrent Childhood Central Nervous System Embryonal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- sunitinib malate, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging, laboratory biomarker analysis
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1921–1944
of 11,433
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ulcerative Colitis
- Interventions
- BBT-401-1S first and then Placebo, Placebo first and then BBT-401-1S
- Drug
- Lead sponsor
- Bridge Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 11
- States / cities
- Sacramento, California • Ventura, California • Boca Raton, Florida + 8 more
- Conditions
- Fragile X Syndrome
- Interventions
- arbaclofen, Placebo
- Drug
- Lead sponsor
- Seaside Therapeutics, Inc.
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Long Beach, California • Sacramento, California + 24 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 18 more
- Conditions
- B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
- Interventions
- Biospecimen Collection, Clinical Evaluation, Neurocognitive Assessment, Questionnaire Administration, Survey Administration
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Years to 39 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Madera, California + 60 more
- Conditions
- NGLY1 Deficiency
- Interventions
- GlcNAc-GlcN, Placebo
- Drug · Other
- Lead sponsor
- Eva Morava-Kozicz
- Other
- Eligibility
- 1 Year to 60 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- zolbetuximab, placebo, oxaliplatin, folinic acid, fluorouracil
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more
- Conditions
- Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
- Interventions
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 170
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 120 more
- Conditions
- Agitation
- Interventions
- acupuncture, sham acupuncture
- Device
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- COVID-19 Pneumonia
- Interventions
- Tocilizumab (TCZ), Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 23
- States / cities
- La Jolla, California • La Mesa, California • Los Angeles, California + 18 more
- Conditions
- Dementia With Lewy Bodies
- Interventions
- CT1812
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
- Conditions
- Attention Deficit Disorder
- Interventions
- Extended-release bupropion hydrochloride
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Chula Vista, California • Lafayette, California + 18 more
- Conditions
- HIV Infections, Pregnancy
- Interventions
- Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 60 Years
- Enrollment
- 1,496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1994
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more
- Conditions
- Psoriatic Arthritis
- Interventions
- 210 mg brodalumab, 140 mg brodalumab, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 31
- States / cities
- Peoria, Arizona • Little Rock, Arkansas • Cypress, California + 26 more
- Conditions
- Extensive Stage Lung Small Cell Carcinoma
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 561
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 362 more
- Conditions
- Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides
- Interventions
- AFM13
- Drug
- Lead sponsor
- Affimed GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more
- Conditions
- Clinical Indication for Brain MRI, Healthy Volunteers
- Interventions
- SyMRI 15 (3D)
- Device
- Lead sponsor
- SyntheticMR
- Industry
- Eligibility
- Up to 99 Years
- Enrollment
- 189 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Naples, Florida • Orlando, Florida + 3 more
- Conditions
- Severe Aplastic Anemia
- Interventions
- Haploidentical donor bone marrow transplant, Unrelated donor bone marrow transplant
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 3 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more
- Conditions
- Obesity
- Interventions
- LAP-BAND System
- Device
- Lead sponsor
- Apollo Endosurgery, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- ZD4054, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 896 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Greenbrae, California • Los Angeles, California + 16 more
- Conditions
- Psoriasis
- Interventions
- Anti IL-12 monoclonal antibody/ABT-874, placebo
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 16
- States / cities
- San Diego, California • Alpharetta, Georgia • Skokie, Illinois + 13 more
- Conditions
- Myeloid Proliferations Associated With Down Syndrome
- Interventions
- Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 90 Days
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 173
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 130 more
- Conditions
- Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease
- Interventions
- Ferric Maltol, Ferric Carboxy Maltose
- Drug
- Lead sponsor
- Shield Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 17
- States / cities
- Dothan, Alabama • Tucson, Arizona • Gainesville, Florida + 14 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- 54 Gy radiotherapy, 60 Gy radiotherapy
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 74
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 62 more